Delcath sells $20m in stock at three-year-low price to advance hepatic chemo system
This article was originally published in Scrip
Executive Summary
Ahead of its new drug application (NDA) filing with the US FDA at the end of the summer, Delcath Systems plundered $20 million on 25 May from the public markets with a bottom-trawling stock offering at the company's lowest stock price in the past three years. The money has been raised to commercialise its Chemosat chemotherapy drug delivery system.